Allucent Granted COVID-19 Booster Vaccine Contract
Agreement with BARDA aims to accelerate development.
Allucent, a clinical research organization (CRO), has officially been chosen to fast-track clinical research and development for new COVID-19 vaccine candidates by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. As part of the contract, Allucent will hold a 10,000-participant Phase IIb clinical trial designed to measure efficacy of next-generation vaccine candidates compared to authorized treatments to prevent symptomatic, PCR-confirmed SARS-CoV-2 infection.
"Allucent is honored to have been chosen by BARDA for this critical initiative," said Mark A. Goldberg, MD, chairman, CEO, Allucent, in a company press release. "This collaboration represents a significant step forward in our collective efforts to combat COVID-19 and its variants. We are excited to leverage our expertise and resources to help develop next-generation booster vaccines that will enhance global immunity and save lives. This award results from our focused investment in countering infectious diseases and further builds upon our growing federally funded clinical trials portfolio."
Reference: Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines. PR Newswire. August 28, 2023. Accessed August 29, 2023. https://www.prnewswire.com/news-releases/allucent-awarded-barda-contract-to-support-acceleration-of-next-generation-covid-19-booster-vaccines-301910678.html
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
